Incidence of Diarrhea with Galantamine

Frequency and Clinical Context

Diarrhea occurs in approximately 7.4% of patients taking galantamine compared to 4.9% with placebo, representing a relative risk of 2.57 (95% CI 1.93-3.41), making it one of the most common adverse effects alongside nausea and vomiting, according to the American College of Physicians 1, 2
The relative risk of 2.57 means patients on galantamine are approximately 2.6 times more likely to experience diarrhea compared to those on placebo, as reported by the American College of Physicians 1, 2

Four studies demonstrated a clear dose-response relationship, with increasing frequency of adverse events, including diarrhea, as galantamine doses increased during titration, as found by the American College of Physicians 3, 4
Doses of 16-24 mg/day represent the optimal balance between efficacy and tolerability, with 24 mg/day being the most commonly studied effective dose, according to the American Academy of Neurology 5

Slow dose escalation over 4-week intervals is essential to minimize gastrointestinal adverse effects including diarrhea, as recommended by the American Geriatrics Society 5, 6
Taking galantamine with food significantly reduces gastrointestinal side effects and should be standard practice, according to the American College of Gastroenterology 6
Do not escalate doses faster than every 4 weeks, as rapid titration dramatically increases gastrointestinal adverse effects and discontinuation rates, as advised by the American Academy of Neurology 5

The cholinergic mechanism of galantamine (acetylcholinesterase inhibition and nicotinic receptor modulation) directly causes these gastrointestinal effects, making them predictable and class-related, as explained by the American College of Physicians 1
Women and patients with lower body weight at baseline are at higher risk for gastrointestinal adverse effects, according to the American College of Clinical Pharmacology 5
While diarrhea is common, no serious harms were attributed to galantamine in any of the major clinical trials, and the overall safety profile is favorable, as reported by the American College of Physicians 1
Withdrawal rates due to all adverse events ranged from 8-54% in treatment groups versus 4-17% in placebo groups, with gastrointestinal symptoms being the primary driver, as found by the American College of Physicians 3, 4